A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

IBD98-M is a delayed-release formulation of mesalamine (mesalazine) and SH with a potential therapeutic role in ulcerative colitis (UC). A total of 51 patients with a modified Ulcerative Colitis Disease Activity Index (UCDAI) score of ≥4 and ≤10, and a modified UCDAI endoscopy su...

Full description

Bibliographic Details
Main Authors: Gionata Fiorino, Giacomo Carlo Sturniolo, Fabrizio Bossa, Andrea Cassinotti, Antonio Di Sabatino, Paolo Giuffrida, Silvio Danese
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cells
Subjects:
IBD98-M
sodium hyaluronate
mesalazine
mesalamine
5-ASA
ulcerative colitis
inflammatory bowel disease
Online Access:https://www.mdpi.com/2073-4409/8/6/523

Internet

https://www.mdpi.com/2073-4409/8/6/523

Similar Items